Background We evaluated the diagnostic discrimination of a new micro-flow cell device (Nanoduct s ) which measures sweat conductivity in situ at a regional referral centre for cystic fibrosis (CF).
Introduction
Measurement of sweat chloride using the quantitative pilocarpine iontophoresis test (QPIT) has been recommended as the de¢nitive analytical approach for sweat testing using sweat collected onto ¢lter paper 1 or as liquid into a capillary coil (Macroduct s ). The ¢lter paper collection procedure is still widely used having changed little since its introduction over 50 years ago, is time consuming and prone to contamination, requires highly skilled sta¡ and separate analytical facilities. Conductivity measurements of liquid sweat were ¢rst described in 1994 2 but have not been recognized as a valid alternative diagnostic test despite several large scale studies having demonstrated excellent discrimination of sweat conductivity between nor-mal and cystic ¢brosis (CF) populations. 3--5 In addition, good comparability between individual centres has been demonstrated in the United Kingdom National External Quality Assessment Scheme (UKNEQAS) for sweat electrolytes. Reluctance to adopt conductivity as a viable alternative arises in part from concern about the diagnostic misclassi¢cation of values in the intermediate range, which are observed in mild presentations with atypical genotype.
A new micro-£ow cell device, Nanoduct s , which measures sweat conductivity in situ has been developed. 6 This device incorporates a conical collecting surface to channel sweat directly and anaerobically from the stimulated sweat ducts to a continuous £ow-through conductivity cell. After an initial period, the duration of which depends on the sweat rate, and incorporating a pre-de¢ned 3-min interval, the conductivity is measured continuously over a 5-min period and averaged to give a ¢nal result.
The equipment was speci¢cally designed to facilitate sweat testing in neonates as it only requires 3 mL of sweat. The whole procedure takes only 15 min to perform, lends itself to point of care testing and dispenses with the need for separate laboratory facilities. We undertook the evaluation of a production prototype at a regional CF unit to which infants, children and adults are referred for diagnostic sweat testing. We compared its diagnostic discrimination with the established QPIT procedure.
Methods

Subject recruitment
There were four groups of subjects. Group1 (n ¼ 6) were infants referred to the regional CF unit for diagnostic follow-up to neonatal screening. (Neonatal screening of blood spots in Wales employs a two-tier testing system. This includes an initial immunoreactive trypsin measurement followed by genetic testing of the top 97th centile for the 31 common disease causing mutations for CF using the ABBOTT OLA CF31 mutation testing kit [Abbot Diagnostics, Maidenhead, Berkshire, UK].) Group 2 (n ¼ 55) were referred because of clinical suspicion of CF. Group 3 (n ¼ 35) were patients with CF attending the regional referral unit for follow-up care and included patients with both classical and nonclassical CF. Group 4 (n ¼ 4) were adult laboratory volunteers.
A diagnosis of CF in all cases was based on clinical assessment supported by sweat chloride measurement, pancreatic exocrine function testing and genotyping.
Genotyping was initially undertaken as for neonatal screening with more extensive analysis of the CF gene undertaken at Manchester Regional Molecular Genetics Laboratory (Royal Manchester Children's Hospital, Manchester M27 4HA). The hospital ethics committee approved the study and informed consent was obtained from the subjects or their guardians.
Analytical methodology
Sweat testing both by QPIT and the Nanoduct was performed at the same time on di¡erent arms. Repeat testing also included sweat testing with the Macroduct system.
QPIT
The QPIT is described elsewhere. 7 Brie£y, after an initial iontophoresis sweat was collected onto ¢lter paper and the sweat eluted. Chloride was measured by coulo-metry and sodium by £ame photometry. The measurement of both chloride and sodium was subject to both internal quality control and external quality assessment. The reference ranges for sweat chloride were those recommended in the UK guidelines 7 (i.e. normal less than 40 mmol/L; intermediate 40--60 mmol/L and diagnostic for CF above 60 mmol/L).
Nanoduct
The design of the Nanoduct has been described in detail elsewhere. 6 Sweat stimulation and measurement of conductivity in situ was performed according to the manufacturer's instructions. The testing involves an initial iontophoresis with miniature pilocarpinecontaining agar gel discs (15 mm in diameter and 6 mm thick). Iontophoresis is performed at 0.5 mA for 2 min, the stimulated area of skin is cleaned and the gel at the anode replaced with the miniature conductivity sensor. After the sweat has reached the second electrode there is a display of the initial sweat rate in g/m 2 / min followed by a ¢xed 3-min interval to allow for the '¢rst sample phenomenon'. Thereafter conductivity is measured continuously over a 5-min period until it plateaus, during which the conductivity is averaged and a numerical reading is displayed. The whole procedure is completed in 15 min. A check on the instrumental electrical circuitry of the Nanoduct was performed daily. The established diagnostic ranges for sweat conductivity were provided by the manufacturer (Wescor, Inc, Logan, UH, USA) and their UK distributor (Chemlab Scienti¢c Products, South¢elds Business Park, Laindon, Essex SS15 6TQ, UK) and have been recommended for use with children up to the age of 15 years: normal 0--60 mmol/L, intermediate 60--80 mmol/L and CF above 80 mmol/L.
Macroduct
The Macroduct system has been described elsewhere. 2 Conductivity measurements in liquid sweat using the Sweat Chekt analyser were controlled using the manufacturers'quality control material and participation in the UKNEQAS sweat-testing scheme. The diagnostic ranges for sweat conductivity measured by the Sweat Chek were the same as for the Nanoduct.
Repeat testing
Repeat testing by QPIT and the Nanoduct was undertaken among Group 2 patients (the diagnostic referrals) if there was a failed sweat test. This is de¢ned as a sweat weight less than 100 mg for the QPIT procedure, as advised by the UK guidelines and calculated for a minimum acceptable sweat rate of 1g/m 2 /min. The same minimum sweat rate was also adopted for the Nanoduct. In addition sweat tests were repeated where practical either using the Nanoduct (but with sensors from a new batch) and/or the Macroduct-collecting device among a number of patients in Group 3 known to have classical CF where the sweat conductivity was less than that of sweat chloride. This is because sweat conductivity should exceed that of sweat chloride by 15 mmol/L 3 . Measurement of conductivity in liquid sweat was also undertaken in three patients with nonclassical CF and three adult volunteers.
Intra-individual variation
Intra-individual variation incorporating both biological and analytical variation was undertaken by repeat testing (n ¼ 6) on an adult volunteer over a 6-month period.
Statistical analysis
Because sweat chloride and conductivity are not normally distributed, non-parametric statistics were employed.
Results
Intra-individual variation
The overall precision comprising the biological and analytical variation conducted on an adult volunteer in whom both the mean sweat chloride and conductivity was 35 mmol/L, was 12% and 10% for the QPIT and Nanoduct, respectively.
Number of failed sweat tests
There were ¢ve failed sweat tests using the conductivity sensor and four using the QPIT.
Diagnostic outcome
There were 110 sweat tests performed by both techniques ( Figure 1 ) on 100 individuals, of whom 42 had a diagnosis of CF. Of these 42 patients, 35 were already diagnosed, three of whom had non-classical CF. Of the seven new diagnoses, four had classical CF: two of these had been identi¢ed through diagnostic referral and two through neonatal screening. Of the remaining three with non-classical CF, one was identi¢ed through neonatal screening and two through diagnostic referral Table 2 .
Among the 36 patients with classical CF, there were 12 homozygotes for DF508, 17 compound heterozygotes for DF508, two compound heterozygotes for R117 H, one compound heterozygote for G85/NK, one homozygote for 621 þ1G4T, one compound heterozygote for N130K/ G149R and two in whom the mutation is not known.
Among the non-classical CF there were four compound heterozygotes with the R117 H mutation (two in association with DF508 and two in association with 621 þ1G4T), one compound heterozygote for DF508/ G81E polyT, and one patient in whom extensive sequencing of the gene failed to identify a known mutation.
Comparison of QPIT and nanoduct
There were nine patients with classical CF in whom the initial conductivity measurement misclassi¢ed the diagnosis. Eight of these patients had intermediate conductivity values (60--80 mmol/L) and one was a false negative. This represents an overall false negative rate of 25% among the 36 patients with classical CF. Repeat testing of these patients with a sensor from a di¡erent batch and/or with the collection of liquid sweat with the Macroduct system gave results concordant with the diagnosis (Table 3) .
Among the six patients with non-classical CF there was one patient (Table 3 , no. 10) --a 19-year old male referred for a diagnostic sweat test --who had intermediate sweat chloride concentration but a normal sweat conductivity on Nanoduct testing. Repeat testing to con¢rm a diagnosis of non-classical CF with the Macroduct system obtained an intermediate chloride concentration and a positive conductivity result. He is clinically considered to have non-classical CF despite detailed examination of the CF gene failing to identify any known mutation. There was concordance of the chloride and the conductivity for the ¢ve other nonclassical CF patients.
There were four other intermediate results:
One 12-year old boy with intermediate chloride and conductivity on one occasion and a normal conductivity on repeat testing in whom no known mutations associated with CF have been identi¢ed and who, on clinical assessment, is not considered to have CF;
One 5-week-old infant with normal sweat chloride; An infant with echogenic bowel on antenatal ultrasound who on testing twice within the ¢rst A bias plot comparing conductivity and chloride ( Figure 2 ) demonstrates that conductivity was negatively biased compared to chloride at high values in the abnormal range. In addition, when conductivity determined in situ by the Nanoduct was compared with conductivity in liquid sweat collected with the Macroduct on individuals who were subjected to repeat testing the non-equivalence was con¢rmed (Figure 3 ). This indicated that the sensors rather than conductivity per se were defective. Photographic examination of a cross-section of one of the sensors from the original batch by the manufacturers demonstrated an occluded £ow path in the cell which would have been partly responsible for underestimation of high conductivity value.
Discussion
Conductivity measurements in liquid sweat using the macroduct system have been documented in 4877 subjects since the equipment was ¢rst introduced. 2--5 The most recent evaluation 5 compared chloride and conductivity in 3834 subjects of whom 294 had a diagnosis of CF. Our study was undertaken to see if the in situ direct reading conductivity measurements o¡ered a more practicable approach to sweat testing without compromising diagnostic accuracy. Since we commenced our study, a similar study has been published with the Nanoduct but comparing conductivity with measurements of chloride and osmolality in liquid sweat. 8 With regard to the analytical performance of the device we obtained comparable values of 10% to van der Merwe et al. 9 for within-subject biological variation for measurement of sweat conductivity. The failure rate of 3% was also comparable to that of the QPIT.
We assumed at the outset that conductivity measured using the Nanoduct would be equivalent to conductivity measured in liquid sweat collected by the Macroduct and measured with the Sweat Chek as advised in the manufacturer's original publication 6 and in the instructions supplied with the device, but we found this to be incorrect. Unlike Barben et al., 8 who obtained 100% sensitivity and 100% speci¢city in diagnosing classical CF, our false negative rate was 25% for patients with classical CF. Retesting with sensors from a di¡erent batch and/or using Macroduct liquid sweat collection achieved the correct diagnostic classi-¢cation. Moreover in the remainder of the subjects (n ¼ 27) with classical CF the majority of conductivity results were negatively biased with respect to chloride. This is at variance with the published data 2,3,5 and the manufacturer's advice. Conductivity should exceed chloride by approximately 15 mmol/L due to the contribution of other unmeasured anions, such as lactate and bicarbonate, in sweat. 3 The median value for conductivity in the 27 classical CF patients was 104 mmol/L compared to a median value for chloride of 119 mmol/ L. Assuming a Gaussian distribution for their data and in a comparable patient population, Barben et al. obtained a mean conductivity of 115 mmol/L compared with 108 mmol/L for chloride which, although positively biased, is a smaller than expected di¡erence between the two measurements.
Conductivity in the non-CF group, however, did exhibit the expected positive bias. The median (SD) conductivity of 37(11) mmol/L equivalent is comparable to the value quoted by Barben et al. and the published data for the Macroduct 2--5 with a median chloride concentration of 24 (10) mmol/L in the ¢lter paper eluate. For ¢ve of the six non-classical CF patients there was concordance with the chloride and conductivity in diagnostic classi¢cation.
A negative bias of Nanoduct conductivity was also demonstrated in comparison to conductivity in liquid sweat when simultaneous sweat testing using the Nanoduct and the Macroduct was undertaken as part of repeat testing on both adult volunteers and CF patients, con¢rming that the two measurements are not equivalent. Unlike the Sweat Chek conductivity analyser used for liquid sweat measurements, there is no external mechanism for verifying accuracy with the Nanoduct apart from the resistance checks on the conductivity measurement circuitry. The di¡erence between the two approaches to measurement is that the Nanoduct measures the sweat conductivity in situ continuously over a 5-min period while the Macroduct measures conductivity in a sample of sweat collected over a 15-min-interval and measured in a separate device. Photographic examination of a cross-section of one of the sensors identi¢ed blockages in the £uid path as the cause of underestimation of the sweat conductivity. In addition the negative bias compared to both chloride and conductivity, which is most pronounced for high values, may re£ect a problem with the electronic averaging of the sweat conductivity at higher values. The manufacturers were advised of this negative bias at high values of conductivity and are currently investigating the cause.
In conclusion, like Barben et al. 8 we found the Nanoduct system to be more user-friendly, practical and the turn-around time for results reduced. However, in contrast to their study we cannot recommend its use for diagnostic testing as we found an unacceptably high false negative rate and an unexpected negative bias for conductivity compared to chloride among patients with classical CF. The manufacturers were informed of our data and have since developed a mechanism for factory checking the sensors prior to distribution.
